In-hospital prognostic value of hemoglobin levels on admission in patients with acute ST segment elevation myocardial infarction undergoing primary angioplasty
- First Online:
- 178 Downloads
Anemia is a common comorbidity in patients presenting with ST-elevation myocardial infarction (STEMI). The aim of this study was to investigate the in-hospital prognostic value of admission hemoglobin (Hb) levels in patients with acute STEMI undergoing primary percutaneous coronary intervention (p-PCI).
This is a retrospective study of 1,625 patients with STEMI stratified by quartiles of admission Hb concentration (Q1 ≤12.5 g/dl, Q2 12.6–13.8 g/dl, Q3 13.9–15.0 g/dl, Q4 ≥15.1 g/dl). Main outcome measures were in-hospital rates of all cause mortality, re-infarction, target vessel revascularization, stroke, heart failure (HF) and bleeding complications.
The incidences of in-hospital mortality according to quartiles from Q1 to Q4 were 8.6, 3.9, 2.4 and 2.6%, respectively (p < 0.001). The incidences of major hemorrhage and HF were significantly higher in Q1, compared to the other quartiles (7.4, 1.9, 3.1, 2.8%, p < 0.001; 16.3, 8.5, 7.7, 9.8%, p < 0.001, respectively). Multiple logistic-regression analysis showed that low admission Hb level (Q1) is an independent and a potent predictor for in-hospital mortality [unadjusted odds ratio (OR): 3.84, 95% confidence interval (CI): 1.78–7.82; p < 0.001].
Lower concentrations of Hb on admission are associated with higher rates of in-hospital mortality, heart failure and major bleeding after p-PCI.
KeywordsHemoglobin Myocardial infarction Percutaneous coronary intervention Prognosis
- 1.Nikolsky E, Aymong ED, Halkin A et al (2004) Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. J Am Coll Cardiol 44:547–553PubMedCrossRefGoogle Scholar
- 11.World Health Organization (1968) Nutritional anemias: report of a WHO Scientific Group. World Health Organization, GenevaGoogle Scholar
- 14.Rao AK, Pratt C, Berke A et al (1988) Thrombolysis In Myocardial Infarction (TIMI) Trial—phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11:1–11PubMedCrossRefGoogle Scholar
- 23.Nikolsky E, Mehran R, Sadeghi M et al (2009) Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction; analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. J Am Coll Cardiol Intv 2:624–632Google Scholar